Attached files
| file | filename |
|---|---|
| 8-K/A - FORM 8-K/A - CAPRICOR THERAPEUTICS, INC. | v400698_8ka.htm |
| EX-10.1 - EXHIBIT 10.1 - CAPRICOR THERAPEUTICS, INC. | v400698_ex10-1.htm |
| EX-10.3 - EXHIBIT 10.3 - CAPRICOR THERAPEUTICS, INC. | v400698_ex10-3.htm |
| EX-10.2 - EXHIBIT 10.2 - CAPRICOR THERAPEUTICS, INC. | v400698_ex10-2.htm |
Exhibit 99.1
CAPRICOR THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
| September 30, 2014 | Pro-Forma Adjustments | Pro-Forma September 30, 2014 | ||||||||||
| ASSETS | ||||||||||||
| CURRENT ASSETS | ||||||||||||
| Cash and cash equivalents | $ | 9,805,435 | $ | 17,052,029 | (1) | $ | 26,857,464 | |||||
| Marketable securities | 325,318 | 325,318 | ||||||||||
| Restricted cash | 3,699,660 | 3,699,660 | ||||||||||
| Grant receivable | 259,800 | 259,800 | ||||||||||
| Interest receivable | 823 | 823 | ||||||||||
| Prepaid expenses and other current assets | 105,100 | 105,100 | ||||||||||
| TOTAL CURRENT ASSETS | 14,196,136 | 17,052,029 | (1) | 31,248,165 | ||||||||
| PROPERTY AND EQUIPMENT, at cost | ||||||||||||
| Furniture and equipment | 38,850 | 38,850 | ||||||||||
| Laboratory equipment | 262,451 | 262,451 | ||||||||||
| Leasehold improvements | 23,744 | 23,744 | ||||||||||
| 325,045 | 325,045 | |||||||||||
| Less accumulated depreciation | (100,499 | ) | (100,499 | ) | ||||||||
| NET PROPERTY AND EQUIPMENT | 224,546 | 224,546 | ||||||||||
| OTHER ASSETS | ||||||||||||
| Patents, net of accumulated amortization of $35,722 at September 30, 2014 | 288,474 | 288,474 | ||||||||||
| Loan fees, net of accumulated amortization of $11,757 at September 30, 2014 | 18,243 | 18,243 | ||||||||||
| In-process research and development, net of accumulated amortization of $0 at September 30, 2014 | 1,500,000 | 1,500,000 | ||||||||||
| Deposits | 55,320 | 55,320 | ||||||||||
| TOTAL ASSETS | $ | 16,282,719 | $ | 17,052,029 | (1) | $ | 33,334,748 | |||||
| LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||||||
| CURRENT LIABILITIES | ||||||||||||
| Accounts payable and accrued expenses | $ | 1,613,066 | $ | 1,613,066 | ||||||||
| Accounts payable and accrued expenses, related party | 300,855 | 300,855 | ||||||||||
| Sub-award payable, related party | - | - | ||||||||||
| Accrued royalties | 111,651 | 111,651 | ||||||||||
| Deferred income, current | 4,166,667 | 4,166,667 | ||||||||||
| TOTAL CURRENT LIABILITIES | 6,192,239 | 6,192,239 | ||||||||||
| LONG-TERM LIABILITIES | ||||||||||||
| Deferred income, net of current portion | 5,208,332 | 5,208,332 | ||||||||||
| Loan payable | 9,155,857 | 9,155,857 | ||||||||||
| Accrued interest | 198,256 | 198,256 | ||||||||||
| TOTAL LONG-TERM LIABILITIES | 14,562,445 | 14,562,445 | ||||||||||
| TOTAL LIABILITIES | 20,754,684 | 20,754,684 | ||||||||||
| STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||||||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding | - | - | ||||||||||
| Common stock, $0.001 par value, 50,000,000 shares authorized, 11,703,774 shares issued and outstanding at September 30, 2014, 16,201,641 shares issued and outstanding Pro-Forma September 30, 2014 | 11,704 | 4,498 | (1) | 16,202 | ||||||||
| Additional paid-in capital | 15,905,010 | 17,047,531 | (1) | 32,952,541 | ||||||||
| Subscription receivable | - | - | - | |||||||||
| Accumulated other comprehensive loss | (1,607 | ) | (1,607 | ) | ||||||||
| Deficit accumulated during the development stage | (20,387,072 | ) | (20,387,072 | ) | ||||||||
| TOTAL STOCKHOLDERS' EQUITY (DEFICIT) | (4,471,965 | ) | 17,052,029 | (1) | 12,580,064 | |||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | $ | 16,282,719 | $ | 17,052,029 | (1) | $ | 33,334,748 | |||||
(1) To reflect the approximate $17,052,029 of cash received from investors in connection with the private placements.